Navigation Links
Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe

Former C.R. Bard and Biosense Webster Executives Join Stereotaxis

ST. LOUIS, April 7, 2008 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS), announced today that it has made two strategic additions to its senior management team. The Company appointed Kevin Shifrin, most recently the Vice President of Global Marketing for the C.R. Bard Peripheral Vascular Division, as Stereotaxis' new Senior Vice President of Global Marketing and Business Development. The Company has also appointed Magnus Holm, most recently Vice President at Biosense Webster Europe Middle East & Africa (EMEA), as the Company's new General Manager for Europe. They will report to Michael P. Kaminski, President and Chief Operating Officer of Stereotaxis.

"Kevin and Magnus are seasoned executives with global marketing and business management experience with major international medical device companies," said Bevil J. Hogg, Chief Executive Officer of Stereotaxis. "Kevin brings more than 15 years of healthcare experience, and his expertise in medical devices, insight into product development and global marketing, and strong connections with physicians worldwide will help us further strengthen our marketing capabilities. Magnus is a highly experienced veteran of the electrophysiology lab and honed his skills with increasing responsibilities in sales, clinical development, market development and business management at Biosense Webster. We believe they can add significant value and experience to our Company as we continue to expand our business, and continue to strengthen our major industry partnerships."

Mr. Shifrin, 42, joins Stereotaxis from C.R. Bard, a developer, manufacturer and marketer of healthcare products in the fields of vascular, urology, oncology and surgical specialty products, where he served as Vice President of Global Marketing for the Peripheral Vascular Division. He joined Bard in 2002 from Cordis Corporation, a subsidiary of Johnson & Johnson, where he served as the Executive Director of Marketing for Cordis Cardiology Europe, and helped oversee the execution of European marketing programs supporting the Cordis stent business. Prior to joining Cordis in 2002, he spent eight years at Bard in a variety of sales, marketing and product management positions with several divisions in the U.S., Europe, Asia, and Latin America.

"I look forward to leading Stereotaxis' global marketing efforts and believe the Company's unique and innovative magnetic navigation system sets the standard of care for treatment of coronary disease and arrhythmia worldwide," said Mr. Shifrin. "I joined Stereotaxis because I see the tremendous potential for the Niobe system and the Odyssey network, as physicians are increasingly called upon to perform highly complex interventional procedures safely and effectively."

Mr. Shifrin earned his MBA in Marketing from the University of Chicago Graduate School of Business in 1991, and his B.S. with honors in Public Administration from the University of Southern California.

Dr. Holm, 44, joins Stereotaxis from Biosense Webster, a leader in technological advancements for the diagnosis and treatment of cardiac arrhythmias, where he served most recently as Vice President of EMEA. In this capacity, Dr. Holm was responsible for sales and marketing and business development throughout the EMEA region. Throughout his 10-year tenure at the Johnson & Johnson subsidiary, Dr. Holm held a variety of positions in market and clinical development and business management.

"Stereotaxis is a growing company dedicated to providing electrophysiologists and other specialists with a safe and effective state of the art system designed for very complex and difficult procedures," said Dr. Holm. "I believe Europe presents a tremendous growth opportunity as more clinical studies are performed and additional EP labs adopt these sophisticated, high-end cardiology solutions."

Prior to joining Biosense Webster in 1997, Dr. Holm spent six years as a hospital engineer and PhD student at the University Hospital in Lund, Sweden. He previously spent four years as a hospital engineer in the clinical physiology department at the Regional Hospital in Kristianstad, Sweden. Dr. Holm earned his PhD in medical science from Lund University, Sweden, in 1997, and his Master of Science degree in biomedical engineering from the Linkoping University in 1987. In 1997, he finished his thesis in clinical electrophysiology on chronic atrial fibrillation.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE Stereotaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Stereotaxis Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
2. Stereotaxis to Present at the Deutsche Bank Small- and Mid-Cap Growth Conference
3. Stereotaxis Receives $20 Million in Additional Loan Commitments
4. Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook
5. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
6. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
7. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
8. Prevent Child Abuse Georgia Appoints New CEO
9. The Cloudburst Group Appoints Pat Shifflett as Vice-President, Health Practice
10. Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer
11. Investigational anti-restenosis drug pimecrolimus disappoints
Post Your Comments:
(Date:11/24/2015)... ... 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, ... , FDA has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) ... not meet the device regulations. , Come up short in an inspection and the ...
(Date:11/24/2015)... Richey, FL (PRWEB) , ... November 24, 2015 , ... ... deems a growing epidemic as deaths from prescription opioids in the United States grew ... and cocaine. In 2013 alone, opioids were involved in 37 percent of all fatal ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the ... of a holiday pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic ... and different way. The location is scheduled to operate through Dec. 24. , Holiday ...
(Date:11/24/2015)... CA (PRWEB) , ... November 24, 2015 , ... Cold Shoulder , LLC launched ... Kickstarter last week and hit their goal of $20,000 in under 10 hours. ... aims to bring the new PRO Weight Loss Vest to the market. , The PRO ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... its exceptional customer service: the TrustDale certification. The award recognizes good companies for ... stone honing , tile and grout, and hard surface restoration company earned this ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Connecticut , November 24, 2015 ... of Acadiana has entered into a multi-year agreement ... imaging centers. This investment will provide the Breast Center ... --> Sectra (STO: SECT B) announces that ... agreement to deploy Breast Imaging PACS in its ...
(Date:11/24/2015)... , Nov. 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ... its Board of Directors has declared a special 1 percent ... dividend is payable December 14, 2015, to shareholders of record ... form of additional shares of common stock. ... Board is a strong endorsement of our confidence in Ascendant,s ...
(Date:11/24/2015)... -- iRhythm Technologies, Inc. , a leading digital health care ... will participate in the 27th Annual Piper Jaffray Healthcare Conference at ... . Kevin King , Chief Executive Officer of ... 8:50am ET. --> --> ... . --> iRhythm is a privately held ...
Breaking Medicine Technology: